<DOC>
	<DOCNO>NCT00004081</DOCNO>
	<brief_summary>RATIONALE : Drugs use chemotherapy use different way stop tumor cell divide stop grow die . PURPOSE : Phase II trial study effectiveness docetaxel treat woman ovarian epithelial cancer primary peritoneal cancer respond previous treatment .</brief_summary>
	<brief_title>Docetaxel Treating Women With Ovarian Epithelial Primary Peritoneal Cancer</brief_title>
	<detailed_description>OBJECTIVES : - Determine activity docetaxel woman platinum resistant , refractory ovarian epithelial primary peritoneal serous cancer . OUTLINE : Patients receive docetaxel IV 30 minute day 1 , 8 , 15 . Courses repeat every 28 day absence disease progression unacceptable toxicity . Patients achieve complete response ( CR ) receive minimum 6 course therapy , include 2 course beyond CR . PROJECTED ACCRUAL : A total 20-30 patient accrue study within 2 year .</detailed_description>
	<mesh_term>Peritoneal Neoplasms</mesh_term>
	<mesh_term>Docetaxel</mesh_term>
	<criteria>DISEASE CHARACTERISTICS : Histologically confirm ovarian epithelial primary peritoneal serous cancer resistant platinum therapy Platinum resistance define one following : Relapse within 6 month platinum base chemotherapy Residual disease completion platinum base chemotherapy Disease progression receive platinum base chemotherapy Marker relapse ( CA125 elevation ) measurable disease Bidimensionally measurable disease exam CT scan PATIENT CHARACTERISTICS : Age : 18 Sex : Female Performance status : ECOG 02 Life expectancy : Greater 2 month Hematopoietic : WBC least 3,000/mm3 Absolute neutrophil count least 1,500/mm3 Platelet count least 100,000/mm3 Hepatic : Bilirubin great upper limit normal ( ULN ) SGPT SGOT great 1.5 time ULN Alkaline phosphatase great 2.5 time ULN Renal : Creatinine great 1.5 mg/dL Cardiovascular : Acceptable cardiac exam No active cardiac ischemia Pulmonary : Acceptable pulmonary exam No active pulmonary infection compromise Other : Not pregnant nursing No severe peripheral neuropathy ( grade 2 great ) No significant psychiatric medical condition would interfere compliance No malignancy within past 3 year , except : Limited basal squamous cell skin cancer Carcinoma situ cervix PRIOR CONCURRENT THERAPY : Biologic therapy : No prior cytokine therapy Chemotherapy : See Disease Characteristics At least 3 week since prior chemotherapy ovarian epithelial peritoneal serous cancer Prior paclitaxel allow No prior docetaxel At least 3 year since prior chemotherapy disease Endocrine therapy : Not specify Radiotherapy : No prior pelvic radiotherapy Surgery : Not specify</criteria>
	<gender>Female</gender>
	<minimum_age>18 Years</minimum_age>
	<maximum_age>N/A</maximum_age>
	<verification_date>August 2012</verification_date>
	<keyword>recurrent ovarian epithelial cancer</keyword>
	<keyword>peritoneal cavity cancer</keyword>
</DOC>